Search for a trial

A Clinical Study of Two Doses of a Selective p38 MAP Kinase Inhibitor, VX-745, to Evaluate the Effects of 12-Week Oral Twice-Daily Dosing on Amyloid Plaque Load as Assessed by Quantitative Dynamic 11C-PiB Positive Emission Tomography (PET) Amyloid Scanning

The primary objective is to assess the effects on amyloid plaque burden of administration of VX-745 for 12-weeks, as assessed by Dynamic 11C-PiB (Carbon-11 labeled Pittsburgh Compound B) PET Amyloid Scanning in patients with Mild Cogntitive…

A Phase 3 Extension, Multicenter, Double-blind, Parallel-Group, Long-term Safety and Tolerability Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Alzheimer Disease Who Are Apolipoprotein E E4 Noncarriers and Participated in Study 3133K1-3000-WW

Primary objectives: To evaluate the long-term safety and tolerability of IV administered bapineuzumab in subjects with AD.Secundary objectives: Efficacy. To explore the long-term efficacy of IV administered bapineuzumab in subjects with AD, using…

A Phase 3 Extension, Multicenter, Long-term Safety and Tolerability Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Alzheimer Disease Who Are Apolipoprotein E ε4 Carriers and Participated in Study 3133K1-3001-WW

Primary objectives: To evaluate the long-term safety and tolerability of IV administered bapineuzumab in subjects with AD.Secundary objectives:To explore the long-term efficacy of IV administered bapineuzumab in subjects with AD, using the following…

Open Label Study of the Effect of Daily Treatment with MPC-7869 in Subjects with Dementia of the Alzheimer*s Type.

Safety-evaluation in case of long term daily usage of MPC-7869. In this Open Label Study , with regard to the safety of MPC-7869, attention will be paid to the amount of AE*s, the physical examinations of subjects, the research of vital functions,…

A behavioral intervention for agitation of people with dementia living at home.

The objective of this study is to develop an evidence-based individualized intervention and to compare the effectiveness of this individualized approach with care as usual to reduce or prevent the increase of agitation (frequency or caregiver…

A Phase 2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AL001 in Heterozygous Carriers of Granulin or C9orf72 Mutations Causative of Frontotemporal Dementia

Primary ObjectivePart1: To evaluate the safety and tolerability of intravenous (IV) administration of AL001 over up to 96 weeks in asymptomatic and symptomatic carriersof a granulin (GRN) mutation causative of frontotemporal dementia (FTD) and in…

Geographic Information System (GIS) based intervention *Viamigo* for people with dementia and their informal caregivers: A single-arm trial to evaluate the feasibility and preliminary participant responses.

The main objective of this study is to evaluate the feasibility of the Viamigo intervention among people with dementia living in the community and their informal caregivers. The secondary objective of this study is to assess the first responses of…

A Multicenter, Open-label Extension (OLE) Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-004 in Patients with C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD)

Primaire Objective: - To evaluate the safety and tolerability of long-term treatment with the study drug in patients with ALS or FTD with a documented mutation in the C9orf72 geneSecondary Objective: - To evaluate the clinical and pharmacodynamic (…

A Phase 1/2 Open-Label, Ascending Dose, Multicenter Study to
Evaluate the Safety and Preliminary Efficacy of AVB-101
Administered by Bilateral Intrathalamic Infusion in Subjects With
Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)

Primary Objectiveo evaluate the safety and tolerability of a one-time, intrathalamic administration of AVB-101 in subjects with FTD-GRN.Secondary Objectiveo To evaluate the preliminary clinical and biomarker measures of efficacy of a one-time,…

A Phase 2a, Open-label, Multicenter Study to Evaluate Biomarkers and Safety of Repeated Administration of NurOwn® (Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors; MSC-NTF cells) in Participants with Prodromal to Mild Alzheimer*s Disease

Primary:• To evaluate AD-specific, neuroinflammatory, neurotrophic and neurodegenerative biomarkers and safety of 3 intrathecal (IT) administrations of NurOwn® (MSC-NTF cells) given at two monthly intervals to participants with prodromal to mild…

A Phase 2a, Open-label, Multicenter Study to Evaluate Safety and Tolerability of Repeated Administration of NurOwn® (Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors; MSC-NTF cells) in Participants with Prodromal to Mild Alzheimer*s Disease

The primary objective is to determine the safety, tolerability and preliminary efficacy of repeated intrathecal administration of NurOwn® (MSC-NTF: Autologous Mesenchymal Stem Cells [MSC] Secreting Neurotrophic Factors [NTF]) given three times at…

Deep Brain Stimulation of the Nucleus Basalis of Meynert in patients with Parkinson's Disease

The primary objective is to investigate the cognitive effect of low-frequency stimulation of the nucleus basalis of Meynert (NBM) in advanced Parkinson*s disease (PD) patients, who were previously treated with deep brain stimulation (DBS) of the…